Skip to content
value.today

Ajax Therapeutics, Inc.

Total raised
$140 M
3 rounds on record
Latest round
$95 M
Apr 2024
First round on record
Jun 2019
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Ajax Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2024$95 MNo. 3$50 to $250 million

Ajax Therapeutics, Inc.: Raise no. 3, Apr 2024

Investors in this round

21 investors had bought by the notice of May 13, 2024: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$95 M of $95 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Martin Vogelbaum · Executive Officer, Director
  • Ramy Farid · Director
  • Ross Levine · Director
  • Scott Platshon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total amount includes committed amounts to be paid to the Issuer in the future.”

Signed by Martin Vogelbaum, Chief Executive Officer. Newest notice filed May 13, 2024. Read the notice at the SEC.

equitySEC
May 2021$37 MNo. 2$10 to $50 million

Ajax Therapeutics, Inc.: Raise no. 2, May 2021

Investors in this round

14 investors had bought by the notice of Jun 1, 2021: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$37 M of $40 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Martin Vogelbaum · Executive Officer, Director
  • Ramy Farid · Director
  • Ross Levine · Director
  • Scott Platshon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Martin Vogelbaum, Chief Executive Officer. Newest notice filed Jun 1, 2021. Read the notice at the SEC.

equitySEC
Jun 2019$8 MNo. 1$2 to $10 million

Ajax Therapeutics, Inc.: Raise no. 1, Jun 2019

Investors in this round

6 investors had bought by the notice of Jun 28, 2019: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Martin Vogelbaum · Executive Officer, Director
  • David Schnell · Director
  • Ramy Farid · Director
  • Ross Levine · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Martin Vogelbaum, Chief Executive Officer. Newest notice filed Jun 28, 2019. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Ajax Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (May 2024).

    SEC Form D · May 2024

  • The industry group it chose in its notices: Other.

    SEC Form D · May 2024

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Ajax Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Ajax Therapeutics, Inc.
NameRoleNamed in
Martin VogelbaumExecutive officerMay 2024
Martin VogelbaumDirectorMay 2024
Ramy FaridDirectorMay 2024
Ross LevineDirectorMay 2024
Scott PlatshonDirectorMay 2024
David SchnellDirectorJun 2019